<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165698</url>
  </required_header>
  <id_info>
    <org_study_id>AS-012 (GLA-CHN-05-01)</org_study_id>
    <nct_id>NCT00165698</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women</brief_title>
  <official_title>Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      To determine the effect and safety of menatetrenone on treatment of postmenopausal
      osteoporosis comparing with alfacalcidol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Density BMD (Percentage) Change in Collum Femoris After 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Density BMD (Percentage) Change in Trochiter After 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Content BMC (Percentage) Change in Lumber Spine After 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Content BMC (Percentage) Change in Collum Femoris After 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Biomarker Osteocalcin (OC) Percentage Change After 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Biomarker Undercarboxylated Osteocalcin (UCOC) Percentage Change After 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Biomarker Undercarboxylated Osteocalcin/Osteocalcin (UCOC/OC) Percentage Change After 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Fracture and Fall</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height (Meter)</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>menatetranone</intervention_name>
    <description>15 mg three times a day orally for 12 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alfacalcidol</intervention_name>
    <description>0.25 μg twice a day orally for 12 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Postmenopausal women with menopause duration more than 5 years and with age between
             45-75 years old (menopausal age ≥40), or if hysterectomy operated before natural
             menopause, the age of women between 60-75 years old.

          -  Subject with BMD (L2-4 or neck of femur) being more than 2 Standard Deviation (SD)
             below the young female adult mean (According to the standard of each center)

          -  BMI between 18 kg/m2-30 kg/m2.

          -  The anatomic structure of lumbar spine must be available for Dual-energy X-ray
             Absorptiometry (DEXA) examination, patient with serious scoliosis, bone trauma or
             sequela after orthopedics surgery, which makes BMD measurement difficult, should be
             excluded

          -  Subject who have given informed consent prior to participation in the trial and who
             undertake to comply with the protocol.

        Exclusion Criteria

          -  Subject with conditions that are considered to effect osteoporosis, such as clear
             definite diabetes mellitus, rheumatoid arthritis, rheumatoid arthritis,
             hyperparathyroidism or other bone metabolic diseases.

          -  Subjects who have received treatment with active-type vitamin D3 preparation, other
             vitamin D preparations (&gt;1000IU per day）, calcitonin, corticosteroid hormone,
             androgen, estrogen, other hormone, vitamin K preparation, in the 3 months prior to
             inanition of this study; Subjects who have received treatment with bisphosphonate
             preparation or Sodium Fluoride in the 1 year prior to inanition of this study;
             Subjects who have received treatment with Selective Estrogen Receptor Modulator (SERM)
             in the 6 months prior to inanition of this study

          -  Concurrent serious renal disease, hepatic disease, uncontrolled hypertension
             （≥150/100mmHg）, symptomatic ischemic heart disease, cerebral infarction or
             arteriosclerosis obliterans.

          -  Cancer history within 5 years.

          -  Subjects who take antacid containing aluminum in the preparation, warfarin or
             thrombolytic agents.

          -  Subject with any known abnormality in laboratory tests, which is deemed to be
             clinically significant by the investigator, which include:

          -  Serum alkaline phosphatace (ALP) &gt; upper normal limit 10% (calculated according to the
             range of normal values of each center);

          -  Glutamic Oxalacetic Transaminase (AST)/ Glutamic Pyruvic Transaminase (ALT) &gt; upper
             normal limit 50％(calculated according to the range of normal values of each center);

          -  Serum creatinine &gt;1.5mg/dL (133μmol/L);

          -  Blood-fasting sugar ≥ 7mmol/L (126mg/L)

          -  Inability of subject to return for scheduled visits or to comply with any other aspect
             of the protocol.

          -  Subject who, in the opinion of the investigator, are poor medical candidates or pose
             any other risk for therapy with an investigational drug.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Hong Di</last_name>
    <role>Study Director</role>
    <affiliation>Eisai China Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hua Dong Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital affiliated to Shanghai Jiaopong University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <results_first_submitted>December 2, 2010</results_first_submitted>
  <results_first_submitted_qc>July 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2011</results_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2014</last_update_posted>
  <responsible_party>
    <name_title>Takao Ishii, Asia regulatory affaires</name_title>
    <organization>Eisai Co., Ltd.</organization>
  </responsible_party>
  <keyword>Postmenopausal</keyword>
  <keyword>osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfacalcidol</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Menatetrenone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Menatetrenone</title>
          <description>15 mg t.i.d. orally for 12 months</description>
        </group>
        <group group_id="P2">
          <title>Alfacalcidol</title>
          <description>0.25 μg b.i.d. orally for 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Taken/Lost the medicine</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Menatetrenone</title>
          <description>15 mg t.i.d. orally for 12 months</description>
        </group>
        <group group_id="B2">
          <title>Alfacalcidol</title>
          <description>0.25 μg b.i.d. orally for 12 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="112"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Baseline Participants are Full Anaylsis Set (FAS) Population</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="6.1"/>
                    <measurement group_id="B2" value="64.2" spread="6.3"/>
                    <measurement group_id="B3" value="64.4" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Per Protocol Set (PPS)</population>
        <group_list>
          <group group_id="O1">
            <title>Menatetrenone</title>
            <description>15 mg t.i.d. orally for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Alfacalcidol</title>
            <description>0.25 μg b.i.d. orally for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months</title>
          <population>Per Protocol Set (PPS)</population>
          <units>percentage of BMD</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" lower_limit="-5.35" upper_limit="14.14"/>
                    <measurement group_id="O2" value="2.17" lower_limit="-15.13" upper_limit="38.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Symbols rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density BMD (Percentage) Change in Collum Femoris After 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Per Protocol Set (PPS)</population>
        <group_list>
          <group group_id="O1">
            <title>Menatetrenone</title>
            <description>15 mg t.i.d. orally for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Alfacalcidol</title>
            <description>0.25 μg b.i.d. orally for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density BMD (Percentage) Change in Collum Femoris After 12 Months</title>
          <population>Per Protocol Set (PPS)</population>
          <units>percentage of BMD</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" lower_limit="-18.51" upper_limit="19.46"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-15.84" upper_limit="13.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Symbols rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density BMD (Percentage) Change in Trochiter After 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Per Protocol Set (PPS)</population>
        <group_list>
          <group group_id="O1">
            <title>Menatetrenone</title>
            <description>15 mg t.i.d. orally for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Alfacalcidol</title>
            <description>0.25 μg b.i.d. orally for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density BMD (Percentage) Change in Trochiter After 12 Months</title>
          <population>Per Protocol Set (PPS)</population>
          <units>percentage of BMD</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" lower_limit="-31.69" upper_limit="87.34"/>
                    <measurement group_id="O2" value="1.76" lower_limit="-38.60" upper_limit="74.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Symbols rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Content BMC (Percentage) Change in Lumber Spine After 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Per Protocol Set (PPS)</population>
        <group_list>
          <group group_id="O1">
            <title>Menatetrenone</title>
            <description>15 mg t.i.d. orally for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Alfacalcidol</title>
            <description>0.25 μg b.i.d. orally for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Content BMC (Percentage) Change in Lumber Spine After 12 Months</title>
          <population>Per Protocol Set (PPS)</population>
          <units>percentage of BMC</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" lower_limit="-9.97" upper_limit="21.59"/>
                    <measurement group_id="O2" value="2.81" lower_limit="-16.88" upper_limit="19.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.869</p_value>
            <method>symbols rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Content BMC (Percentage) Change in Collum Femoris After 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Per Protocol Set (PPS)</population>
        <group_list>
          <group group_id="O1">
            <title>Menatetrenone</title>
            <description>15 mg t.i.d. orally for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Alfacalcidol</title>
            <description>0.25 μg b.i.d. orally for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Content BMC (Percentage) Change in Collum Femoris After 12 Months</title>
          <population>Per Protocol Set (PPS)</population>
          <units>percentage of BMC</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" lower_limit="-12.50" upper_limit="29.63"/>
                    <measurement group_id="O2" value="0.95" lower_limit="-21.24" upper_limit="15.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.174</p_value>
            <method>symbols rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Biomarker Osteocalcin (OC) Percentage Change After 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Per Protocol Set (PPS)</population>
        <group_list>
          <group group_id="O1">
            <title>Menatetrenone</title>
            <description>15 mg t.i.d. orally for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Alfacalcidol</title>
            <description>0.25 μg b.i.d. orally for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Biomarker Osteocalcin (OC) Percentage Change After 12 Months</title>
          <population>Per Protocol Set (PPS)</population>
          <units>percentage of OC</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.67" lower_limit="-67.26" upper_limit="1.33"/>
                    <measurement group_id="O2" value="-25.77" lower_limit="-65.66" upper_limit="57.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>symbols rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Biomarker Undercarboxylated Osteocalcin (UCOC) Percentage Change After 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Per Protocol Set (PPS)</population>
        <group_list>
          <group group_id="O1">
            <title>Menatetrenone</title>
            <description>15 mg t.i.d. orally for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Alfacalcidol</title>
            <description>0.25 μg b.i.d. orally for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Biomarker Undercarboxylated Osteocalcin (UCOC) Percentage Change After 12 Months</title>
          <population>Per Protocol Set (PPS)</population>
          <units>percentage of UCOC</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-82.27" lower_limit="-97.27" upper_limit="676.60"/>
                    <measurement group_id="O2" value="-34.83" lower_limit="-92.07" upper_limit="950.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>symbols rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Biomarker Undercarboxylated Osteocalcin/Osteocalcin (UCOC/OC) Percentage Change After 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Per Protocol Set (PPS)</population>
        <group_list>
          <group group_id="O1">
            <title>Menatetrenone</title>
            <description>15 mg t.i.d. orally for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Alfacalcidol</title>
            <description>0.25 μg b.i.d. orally for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Biomarker Undercarboxylated Osteocalcin/Osteocalcin (UCOC/OC) Percentage Change After 12 Months</title>
          <population>Per Protocol Set (PPS)</population>
          <units>percentage of UCOC/OC</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.64" lower_limit="-94.49" upper_limit="1185.50"/>
                    <measurement group_id="O2" value="-8.47" lower_limit="-85.68" upper_limit="610.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>symbols rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Fracture and Fall</title>
        <time_frame>12 months</time_frame>
        <population>Per Protocol Set (PPS)</population>
        <group_list>
          <group group_id="O1">
            <title>Menatetrenone</title>
            <description>15 mg t.i.d. orally for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Alfacalcidol</title>
            <description>0.25 μg b.i.d. orally for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>New Fracture and Fall</title>
          <population>Per Protocol Set (PPS)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Height (Meter)</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Per Protocol Set (PPS)</population>
        <group_list>
          <group group_id="O1">
            <title>Menatetrenone</title>
            <description>15 mg t.i.d. orally for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Alfacalcidol</title>
            <description>0.25 μg b.i.d. orally for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Height (Meter)</title>
          <population>Per Protocol Set (PPS)</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.05"/>
                    <measurement group_id="O2" value="1.55" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.06"/>
                    <measurement group_id="O2" value="1.55" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety Population</desc>
      <group_list>
        <group group_id="E1">
          <title>Menatetrenone</title>
          <description>15 mg t.i.d. orally for 12 months</description>
        </group>
        <group group_id="E2">
          <title>Alfacalcidol</title>
          <description>0.25 μg b.i.d. orally for 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Parathyroid malignant tumor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>NTT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Goiter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Tendon damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Nerve sheath tumor surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Uterus resection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Cardiovascular system</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Heart rate and rhythm disorders</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic anomalies</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Others</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal liver system</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal system abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central and peripheral nervous system abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary system abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal on skin and its subsidiary tissues</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Takao Ishii, Asia regulatory affaires</name_or_title>
      <organization>Eisai Co., Ltd.</organization>
      <phone>81-3-3817-3914</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

